For laboratory use only. This product is intended for animal research only and not for use in humans.
ReninSense 680 FAST™ is a member of a family of activatable fluorescent imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that confers an improved pharmacokinetic profile with a broader range of early imaging timepoints. This architecture also offers higher target specific signal with reduced background.
ReninSense 680 FAST is a Renin activatable agent that is optically silent upon injection and produces fluorescent signal after cleavage by renin produced in the kidneys. The Renin-Angiotensin System (RAS) is the hormone system involved in regulating blood pressure and fluid balance in the body.
ReninSense 680 FAST is recognized and activated by rodent forms of renin in preclinical animal models. ReninSense 680 FAST may be used to monitor abnormal RAS function, progression of disease and the efficacy of therapeutic treatment in disorders such as hypertension and cardiovascular disease and some neurological diseases.
| Fluorescent Agent Type | Activatable |
|---|---|
| Optical Imaging Classification | Fluorescence Imaging |
| Product Brand Name | ReninSense |
| Quantity in a Package Amount | 1.0 Units |
| Shipping Condition | Blue Ice |
| Unit Size | 1 Vial (10 doses) |
| Wave Length | 680 nm |
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
ReninSense 680 FAST activatable fluorescent imaging agent
ReninSense 680 FAST™ is a member of a family of activatable fluorescent imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that confers an improved pharmacokinetic profile with a broader range of early imaging timepoints. This architecture also offers higher target specific signal with reduced background.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.
Fluorescent Imaging Agent Panel – Toxicology
List Price : USD3372.0
